At this stage I’m seriously questioning what near term value remains here.
The share price is falling almost daily. There are no confirmed catalysts between now and 30 June — no data releases, no commercial outcomes, nothing.
The company had previously indicated we’d see updates for CF33/Vaxinia and OnCARlytics this quarter. Now that guidance has been walked back without explanation, and the latest shareholder letter avoids giving any firm dates or deliverables.
I’d welcome any informed views here — what is the short-term value proposition now? Because from where I’m standing, what’s left of my capital is exposed, particularly leading up to tax selling season and management’s silence and delays is only making it worse. Without news and with imminent dilution we could see 1c in the next 4 weeks. What could possible cause a re-rate within the next 8 weeks?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
26.0¢ |
Change
-0.005(1.89%) |
Mkt cap ! $76.45M | |||
| Open | High | Low | Value | Volume |
| 26.5¢ | 26.5¢ | 25.5¢ | $171.9K | 659.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 87000 | 26.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.5¢ | 127497 | 10 |
View Market Depth
| Last trade - 10.07am 11/08/2025 (20 minute delay) ? |
| IMU (ASX) Chart |